How often is Remicade (infliximab) typically given for Crohn’s disease?
Remicade (infliximab) is usually given by intravenous (IV) infusion in a maintenance pattern that starts after an initial loading period. A common schedule is:
- Induction (start-up): doses at weeks 0, 2, and 6
- Maintenance: then every 8 weeks thereafter
Exact timing can vary based on how well symptoms respond and whether the dose needs adjustment.
What changes the dosing interval—every 8 weeks vs more frequent?
Doctors may shorten the interval (for example, dosing more often than every 8 weeks) if Crohn’s disease symptoms return or if drug levels are low. They may also increase the interval only in selected patients with sustained control. Dose adjustments are typically guided by the patient’s response and, in some practices, drug trough levels and antibodies.
Is it the same for every type of Crohn’s disease?
Maintenance dosing frequency is generally based on overall treatment response rather than one single Crohn’s “type.” Patients with more active disease, prior treatment failures, or higher inflammatory burden are more likely to need interval adjustments.
What about restarting after missed doses or stopping?
If infusions are missed, clinicians often reassess disease control before continuing, and they may adjust the plan to reduce the risk of infusion reactions. If Remicade is stopped and later restarted, dosing may be handled differently from initial induction depending on how long the gap was and how the patient previously tolerated treatment.
How is Remicade administered during each visit?
Each infusion is delivered through a vein (IV) on an outpatient schedule. The timing between visits follows the maintenance interval (often every 8 weeks after induction), and clinicians may use supportive measures such as premedication depending on prior reactions.
Sources
No sources were provided in the prompt. If you share the product label details or the prescribing information you’re using (or allow web lookup), I can cite the exact dosing schedule from that source.